We are live on
!
Find out more
Corvus Pharmaceuticals
CRVS
CRVS
52 hedge funds and large institutions have $28M invested in Corvus Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
1% more call options, than puts
Call options by funds: $114K | Put options by funds: $113K
0% more funds holding
Funds holding: 52 → 52 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
2.68% less ownership
Funds ownership: 41.86% → 39.18% (-2.7%)
37% less capital invested
Capital invested by funds: $44.6M → $28M (-$16.6M)
Holders
52
Holders Change
–
Holders Change %
0%
% of All Funds
0.83%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
10
Increased
15
Reduced
11
Closed
10
Calls
$114K
Puts
$113K
Net Calls
+$1K
Net Calls Change
+$7K
Top Buyers
| 1 |
SC
Samlyn Capital
New York
|
+$634K |
| 2 |
TL
TowerView LLC
New York
|
+$291K |
| 3 |
Millennium Management
New York
|
+$228K |
| 4 |
Two Sigma Advisers
New York
|
+$148K |
| 5 |
JP Morgan Chase
New York
|
+$145K |
Top Sellers
| 1 |
AG
Artal Group
Luxembourg
|
-$1.15M |
| 2 |
CA
CHI Advisors
New York
|
-$458K |
| 3 |
CIC
Cornercap Investment Counsel
Atlanta,
Georgia
|
-$223K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$213K |
| 5 |
Renaissance Technologies
New York
|
-$144K |
